x

¿Aún no está registrado?

Cree su cuenta. Regístrese en Elsevier y obtendrá: información relevante, máxima actualización y promociones exclusivas.

Registrarme ahora
Ayuda - - Regístrese - Teléfono 902 888 740
Buscar en

FI 2015

0,800
© Thomson Reuters, Journal Citation Reports, 2015

Indexada en:

SCIE/Journal of Citation Reports, Index Medicus/Medline, Excerpta Medica/EMBASE, SCOPUS, CANCERLIT, IBECS

Métricas

  • Factor de Impacto: 0,800(2015)
  • 5-años Factor de Impacto: 0,753
  • SCImago Journal Rank (SJR):0,23
  • Source Normalized Impact per Paper (SNIP):0,264
doi: 10.1016/S0210-5705(03)79068-2
Nuevas perspectivas terapéuticas en el esófago de Barrett
A. Lanas
Sección de Gastroenterología Oncológica. Hospital Clínico Universitario de Zaragoza. España
El Texto completo solo esta disponible en PDF
Bibliografía
1.
S.J. Spechler
Barrett's esophagus
N Engl J Med, 346 (2002), pp. 836-842
2.
J. Lagergren,R. Bergström,A. Lindgren,O. Nyrén
Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
N Engl J Med, 340 (1999), pp. 825-831
3.
W.K. Hirota,T.M. Loughney,D.J. Lazas,C.L. Maydonovitch,V. Rholl
Wong RKH. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data
Gastroenterology, 116 (1999), pp. 277-285
4.
J. Alcedo,A. Lanas,A. Ferrández,F. Sopeña,J. Arenas
Trends in the epidemiology and outcome of Barrett's esophagus in Spain
Gut, 51 (2002), pp. 27
5.
C. Morales,R.F. Souza,S.J. Spechler
Hallmarks of cancer progression in Barrett's oesophagus
Lancet, 360 (2002), pp. 1587-1589
6.
V.N. Shirvani,R. Ouatu-Lascar,B.S. Kaur,B. Omary,G. Triadafilopoulos
Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure
Gastroenterology, 118 (2000), pp. 487-496
7.
A.P. Weston,S.K. Banerjee,P. Sharma,T.M. Tran,R. Richards,R. Cherian
p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression
Am J Gastroenterol, 96 (2001), pp. 1355-1362
8.
B.J. Reid,D.S. Levine,G. Longton,P.L. Blount,P.S. Rabinovitch
Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low-and highrisk patient subsets
Am J Gastroenterol, 95 (2000), pp. 1669-1676
9.
R.E. Sampliner
Updated guidelines for the diagnosis, surveillance and therapy of Barrett's esophagus
Am J Gastroenterol, 97 (2002), pp. 1888-1895
10.
W. Ye,W.H. Chow,J. Lagergren,L. Yin,O. Nyren
Risk of adenocarcinoma of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery
Gastroenterology, 121 (2001), pp. 1286-1293
11.
J.A. Jankowski,D. Provenzale,P. Moayyedi
Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west
Gastroenterology, 122 (2002), pp. 588-590
12.
P. Sharma
An update on strategies for eradication of Barrett's mucosa
Am J Med, 111 (2001), pp. 147-152
13.
J. Van den Boogert,R. Van Hillegersberg,P.D. Siersema,R.W.F. De Bruin,H.W. Tilanus
Endoscopic ablation therapy for Barrett's esophagus with high-grade dysplasia: a review
Am J Gastroenterol, 94 (1999), pp. 1153-1160
14.
B.F. Overholt,M. Panjehpour,J.M. Haydek
Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients
Gastrointest Endosc, 49 (1999), pp. 1-7
15.
R.J. Pacifico,K.K. Wang
Role of mucosal ablative therapy in the treatment of the columnar-lined esophagus
Chest Surg Clin N Am, 12 (2002), pp. 185-203
16.
M.J. Langman,K.K. Cheng,E.A. Gilman,R.J. Lancashire
Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database
Br Med J, 320 (2000), pp. 1642-1646
17.
G.P. Morgan,J.G. Williams
Tumouricidal effect of indomethacin in the esophagus
Postgrad Med J, 69 (1993), pp. 960
18.
N.S. Buttar,K.K. Wang,M.A. Anderson,R.A. Dierkhising,R.J. Pacifico,K.K. Krishnadath
The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epitelium: an in vitro study
J Natl Cancer Inst, 94 (2002), pp. 422-429
19.
N.S. Buttar,K.K. Wang,O. Leontovich,J.Y. Westcott,R.J. Pacifico,M.A. Anderson
Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitores in an animal model of Barrett's esophagus
Gastroenterology, 122 (2002), pp. 1101-1112
20.
B.S. Kaur,N. Khamnehei,M. Iravani,S.S. Namburu,O. Lin,G. Triadafilopoulos
Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus
Gastroenterology, 123 (2002), pp. 60-67
21.
A. Lanas,F. Soteras,P. Jiménez,I. Fiteni,E. Piazuelo,Y. Royo,J. Ortego
Superoxide anion and nitric oxide in high-grade esophagitis induced by acid and pepsin in rabbits
Dig Dis Sci, 46 (2001), pp. 2733-2743
22.
H. Akgun,J. Lechago,M. Younes
Estrogen receptor-beta is expressed in Barrett's metaplasia and associated adenocarcinoma of the esophagus
Anticancer Res, 22 (2002), pp. 1459-1461
Copyright © 2003. Elsevier España, S.L.